THE OPTIMAL TREATMENT DURATION OF ADJUVANT AROMATASE-INHIBITOR THERAPY IN POSTMENOPAUSAL BREAST CANCER
For postmenopausal women with hormone receptor–positive breast cancer, the most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear. The SALSA trial now demonstrates that in women who had received 5 years of adjuvant endocrine therapy, extending hormone therapy by 5 years provided no benefit over a 2-year extension but was associated with a greater risk of clinical bone fractures… Read more
CENTRAL VENOUS ACCESS DEVICES FOR THE DELIVERY OF SYSTEMIC ANTICANCER THERAPY
Hickman-type tunnelled catheters (Hickman), peripherally inserted central catheters (PICCs), and totally implanted ports (PORTs) are used to deliver systemic anticancer treatment (SACT) via a central vein. The Cancer and Venous Access (CAVA) trial aimed to compare complication rates and costs of the three devices to establish acceptability, clinical effectiveness, and cost-effectiveness of the devices for patients receiving SACT… Read more
OUTCOME OF BREAST CANCER PATIENTS WITH LOW HORMONE RECEPTOR POSITIVITY
As treatment recommendations for breast cancer patients with low hormone receptor (HR) expression (1-9%) are ambiguous, a population-based 15-year cohort from the Munich Cancer Registry was used to compare patient characteristics and outcome of HR low positive tumours with HR negative and HR strongly positive tumours. Results from this analysis reveal that current definitions for HR positivity and its clinical relevance should be reconsidered... Read more
GENE EXPRESSION SIGNATURES FOR TAILORING ADJUVANT CHEMOTHEARPY OF LUMINAL BREAST CANCER
Oncologists treating early breast cancer patients are often confronted with the dilemma of avoiding undertreatment while minimising the risk of overtreatment. In recent years, three biomarker-based clinical trials (MINDACT, TAILOR-x and Rx-PONDER) have provided strong evidence of safely foregoing chemotherapy in older postmenopausal women with luminal breast cancer at high clinical risk but low genomic risk... Read more
UPDATED SIOG PRIORITIES FOR THE GLOBAL ADVANCEMENT OF CARE FOR OLDER ADULTS WITH CANCER
In 2011, the International Society of Geriatric Oncology (SIOG) published the SIOG 10 Priorities Initiative, which defined top priorities for the improvement of the care of older adults with cancer worldwide. As many progress has been made since then, SIOG has updated its priority list and hopes that it will offer guidance for international and national endeavours to provide adequate universal health coverage for older adults with cancer… Read more
Top
